Shannen Doherty has shared a heartfelt tribute to her cancer treatment team as she finishes up her latest round of radiotherapy. The Charmed star was diagnosed with breast cancer in 2015 and has shared her journey through treatment with her fans by posting photo and video updates on social media.
Category: Oncology
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
… revenue will propel innovation, the costs are stoking patients’ distress and creating a rift between manufacturers, health authorities and payers in many markets. Take the new lung-cancer drugs from Merck & Co., Bristol-Myers Squibb Co. and Roche …
Comments
DECEMBER 22, 2016 – Portrait of Tabitha Wegner and her children Gage, 9 and Nevaeh, 10 at their Windsor home on December 22, 2016. Tabitha Wegner won’t see her children grow up and fall in love.
Rutherglen professor’s fight against cancer recognised with OBE
… has provided abundant opportunities for scientific discovery as well as important challenges for human and animal health. “It has also been a special privilege to realise a personal vision in the development of the research complex on the University …
Woman wants to share battle with ovarian cancer
And now, Newman-Overton is a woman in the middle of the fight of her life with stage four ovarian cancer, living a story . “Why is no one telling this?” Newman-Overton says.
Oncology Drug Report – Kadcyla – ado-trastuzumab emtansine -…
Kadcyla : Armed antibody is a comprehensive report on the first USFDA approved drug with antibody-drug conjugate for HER2-positive metastatic breast cancer treatment. Kadcyla falls in the monoclonal antibody, HER 2-targeted antibody-drug conjugate, class of drugs belonging to the targeted therapy.
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration
… of the past 10 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672). Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of …
Hemispherx BioPharma CEO Talks About Ampligen, Alferon’s Potential
Hemispherx BioPharma, Inc is a nano-cap biopharmaceutical research and development company that focuses on the treatment of seriously debilitating disorders. Its flagship products include Alferon N Injection, Ampligen and Alferon LDO.
A startup trying to get the human body to fight cancer just filed for an IPO
In this 2011 image, tiny beads are used to force T-cells to divide before they are given to leukemia patients. The filing includes a target of $75 million in the public offering, though that’s a placeholder and likely to change.
Social isolation may worsen breast cancer outcomes
… to a study recently published in the journal Cancer . Although the study finds a link between social ties and health, it doesn’t prove that strong social support actually prolongs life, said coauthor Wendy Chen, a breast cancer medical oncologist at …
Immunotherapy offers hope to cancer patients
Three months before physicians at Medical University Hospital discharged Madelyn Graf to hospice – some of them convinced that her cancer was incurable and her death was imminent – she came home from the gym perfectly healthy except for a stomach ache. But the pain became progressively intense that afternoon, wrapping around her torso.
UNCSA designers develop wigs for hair-loss patients
… name on a list for a medical wig. She learned that wig designers at UNC School of the Arts had teamed up with Novant Health, the owner of Forsyth Medical Center, to build free custom wigs for patients with hair loss. The wig designers are students …
We’re Bullish on Wide-Moat Amgen
Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, and free cash flow as a percentage of sales hovers near 40% as the company undertakes massive cost-cutting and improves manufacturing. Strong newer blockbusters like Prolia/Xgeva and future blockbuster Repatha should defend Amgen’s wide economic moat from erosion caused by biosimilar and branded competition.
Mariah Carey entertains woman living with breast cancer
Christmas arrived a week early for a smiling Larissa Podermanski when she met pop star Mariah Carey Saturday backstage at the Beacon Theater in New York City. Fast-forward to the end of a fairytale night when Podermanski , who grew up in Middletown and Middlefield, spoke to Carey , an international musical diva, during a 15-minute private interlude backstage.
Investor Alert: Investigation of NovoCure Limited Announced by The Wagner Firm
Injured investors are encouraged to contact The Wagner Firm to discuss their legal rights, and a potential class action lawsuit to recover investors’ losses. NovoCure develops and commercializes oncology treatments.
Chemo and radiation cancer treatments save children’s lives but may cause ‘late effects’ years later
… “late effects” of cancer treatments. Many of these researchers work in clinics designed specifically to monitor the health of childhood cancer survivors and alert them to potential risks.With the ranks of survivors swelling, there is an urgent need …
Cancer treatments that save childrena s lives exact a heavy price years later
… focusing intently on “late effects.” Many of these researchers work in clinics designed specifically to monitor the health of childhood cancer survivors and alert them to potential risks. With the ranks of survivors swelling, there is an urgent need …
Uniform Advantage Donates More Than $5,000 to Living Beyond Breast Cancer
… a metastatic form of the disease. Resources are developed in collaboration with the nation’s leading oncologists, health professionals and ally organizations and are delivered by people who understand the physical and emotional complexities of …
The Most Likely Incyte Acquisition Deal for 2017?
Could another acquisition involving Incyte be more likely, though? Here are some potential 2017 acquisition scenarios for Incyte: with Gilead, Agenus There are plenty of reasons why Gilead might want to buy Incyte next year. The big biotech has plenty of cash to spend.
The Most Likely Incyte Acquisition Deal for 2017?
Could another acquisition involving Incyte be more likely, though? Here are some potential 2017 acquisition scenarios for Incyte: with Gilead, Agenus There are plenty of reasons why Gilead might want to buy Incyte next year. The big biotech has plenty of cash to spend.
Kidney Cancer Therapeutic and Drug Pipeline Review H2
PUNE, INDIA, December 23, 2016 / EINPresswire.com / — GET SAMPLE REPORT @ Summary Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer – Pipeline Review, H2 2016, provides an overview of the Kidney Cancer pipeline landscape. Kidney cancer also called renal cancer is a disease in which kidney cells become malignant and grows out of control, forming a tumor.
Medical Imaging Technologies for Oncology Diagnostics Market Snapshot …
… some other companies operating in global medical imaging technologies for oncology diagnostics market are Carestream Health, Inc., McKesson Corporation and Techniscan Medical Systems, Inc.
Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, would like to wish all Cellceutix shareholders, their families and friends a happy and healthy holiday season. In 2016, Cellceutix remained extremely transparent in keeping shareholders current on developments, including comprehensive updates via news releases and corporate presentations covering the status of clinical trials and anticipated milestones pertaining to those trials for 2017.
Report: Charleston VA employees ‘improperly’ handled appointment records
A new federal report has determined that patient appointment requests at Charleston’s Ralph H. Johnson VA Medical Center were sometimes marked “discontinued” or “completed” when it was not clear that veterans had been seen yet by outside health care providers. In one case, an elderly patient with advanced liver cancer was referred by the VA to an outside radiation oncologist in mid-2012.
FDA Grants Accelerated Approval to Rubraca for Advanced Ovarian Cancer
The FDA has granted accelerated approval to rucaparib to treat women with a certain type of ovarian cancer. Rucaparib is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation , as identified by an FDA-approved companion diagnostic test.
Health Highlights: Dec. 20, 2016
The therapy features lasers and a drug made from deep sea bacteria, and does not cause severe side effects, BBC News reported. A clinical trial of 413 prostate cancer patients at 47 hospitals across Europe found that 49 percent had no remaining trace of cancer after undergoing the treatment.
Scientists Find New Gene Tool for Predicting Course of Prostate Cancer
… their tool outperformed other scientific methods, and they have applied for a U.S. patent. The National Institutes of Health and Wilmot Cancer Institute/Roswell Park Cancer Institute Collaboration Pilot Funds supported the research. Chief …
Blog: Where is the TV camera?
With Christmas fast approaching, the inflation of charitable events has been taking over Slovakia. Yes, it’s that time of the year when I wish people noticed that children’s hospitals have more wards than the “oncology” one.
Lasers a transforma prostate treatment
The approach, tested across Europe, uses lasers and a drug made from deep sea bacteria to eliminate tumours, but without causing severe side effects. Trials on 413 men published in The Lancet Oncology showed nearly half of them had no remaining trace of cancer.
10 cancer symptoms you could be missing
If something appears unusual and doesn’t go away in a couple of weeks, get it checked out. Photo / Getty Most of us think we know the telltale signs of cancer: a lump in the breast, unexplainable tiredness, sudden weight loss… but experts are pointing to lesser known symptoms to watch out for that may lead to earlier detection of the disease.
Local nonprofit makes $100,000 commitment to Advocate Children’s Hospital
Andrew Smialek was just 14 years old when he was diagnosed with Hodgkin lymphoma. He spent his high school years and first year of college undergoing chemotherapy, as well as stem cell and bone marrow transplants.
New Ovarian Cancer Drug Wins Speedy FDA Approval
U.S. health officials have approved a new option for some women battling ovarian cancer: a drug that targets a genetic mutation seen in a subset of hard-to-treat tumors. The Food and Drug Administration cleared the drug, Rubraca, from Clovis Oncology Inc. for women in advanced stages of the disease who have already tried at least two chemotherapy drugs.
This drugmaker is taking an unprecedented approach to getting its cancer treatment approved
As researchers look for new approaches for tough-to-treat cancer, many are looking into genetics – more specifically, they’re looking at the type of genetic mutations found in cancerous tumors. One company in particular, called Loxo Oncology is building drugs that act on those mutations, so that the type of cancer someone has wouldn’t matter so much as the genetic information gleaned from sequencing the tumor.
Long-term anti-inflammatory drug use may increase cancer-related deaths for certain patients
… Felix, PhD, co-lead author of the study and cancer epidemiologist with the OSUCCC – James and College of Public Health. “These results are intriguing and worthy of further investigation,” says David Cohn, MD, gynecologic oncology division director …
AMP publishes joint guidelines for interpretation, reporting of sequence variants in cancer
The Association for Molecular Pathology , the premier global, non-profit molecular diagnostics professional society, today published guideline recommendations for both clinical laboratory professionals and oncologists that assess the status of next-generation sequencing -based cancer tests and establish standardized classification, annotation, interpretation, and reporting conventions for somatic sequence variants. The new guideline was developed by a Working Group comprised of representatives from major professional associations whose members provide professional testing and treatment services to cancer patients.